Anjali Advani, MD completed her undergraduate training with Honors in Chemical Engineering at Princeton University and went on to pursue her medical school, residency, and fellowship at Duke University School of Medicine. She is currently a Staff Physician in the Department of Hematology/ Oncology and Director of the Inpatient Leukemia Unit at Cleveland Clinic Taussig Cancer Institute. Dr. Advani is also Professor of Medicine in the Cleveland Clinic Lerner College of Medicine and Chair of the Data Safety and Monitoring Committee for Case Comprehensive Cancer Center. Her major clinical interest includes acute leukemias, with a particular emphasis on molecular targeted therapies and novel treatment strategies for acute myeloid leukemia and acute lymphoblastic leukemia. She is a member of the SWOG Leukemia Committee, SWOG Hope Foundation, NCI Leukemia/ Lymphoma Pediatric Steering Committee, and American Society of Hematology Education Committee.
Nicolas Boissel is Head of the Adolescent and Young Adults Unit, Department of Haematology, Saint-Louis Hospital, and Professor of Medicine at University Paris Diderot, Paris, France. After beginning his career as a research fellow at the Pasteur Institute and as an intern at Paris Municipal Hospitals, he did a PhD at the Department of Immunology at Saint-Louis Hospital in 2002 while completing his MD at the University of Paris VI. In 2005, he went on to become Assistant Professor at Saint-Louis hospital in the Acute Leukemia unit headed by Professor Hervé Dombret, before taking up his current position in 2010. He is engaged in therapeutics for patients with bone marrow disorders including acute leukaemia, lymphoma, and aplastic anaemia, with a specific focus of adolescent and young adult comprehensive care. He is the chairman of the French Oncohematology Group for Adolescents and Young Adults (GO-AJA). As member of French national cooperative groups for acute lymphoblastic leukaemia (GRAALL) and acute myeloid leukaemia (ALFA), he is involved in many trials designed to improve the outcome of acute leukaemia patients. His clinical research interests include the role of new oncogenic events and minimal-residual disease to stratify therapeutic approaches in acute leukaemia, and the development of immunotherapy in the field.
Monika Brüggemann is Head of the Section for Hematology Diagnostics at University Hospital Kiel, Germany. She is also a Professor in the Faculty of Medicine at Christian-Albrechts University in Kiel. After completing her medical degree and PhD at the University of Essen, Germany, Dr Brüggemann specialised in lymphoid malignancies, undertaking postdoctoral fellowships in the Division of Hematology and Oncology at the University of Göttingen, Germany and in the Department of Medicine at the University of Essen. Moving to the Schleswig Holstein University Medical Center, Campus Kiel in 1998, she was part of the team that initiated the Labor für Hämatologische Spezialdiagnostik (Laboratory for Haematological Special Diagnostics), which has become one of the leading national and international haematological laboratories, focusing on minimal residual disease (MRD) diagnostics. She assumed her current position in 2015. The recipient of the 2011 Fritz Acker Memorial Award for clinical research in haemato-oncology, Dr Brüggemann’s current research focuses on molecular genetics and MRD diagnostics of lymphoproliferative diseases, and she is currently coordinating several multicentre MRD studies in lymphoid malignancies. She is also a board member of several different international networks in the field of haematology, including the EuroMRD and EuroFlow networks.
Yves Chalandon is born in Geneva and has made his studies in Geneva. He is board certified in Internal Medicine and in Hematology. He did a fellowship in Vancouver on hematopoietic stem cell transplantation and his research work was on leukemogenesis with Connie Eaves (Terry Fox Laboratory). When coming back to Geneva he has been highly involved in allogeneic hematopoietic stem cell transplantation and hematological malignancies. His research work is on immune reconstitution post alloHSCT, on chronic malignancies at the EBMT (CMWP), on alloHSCT at the SFGM-TC and on hematological malignancies, mainly leukemia within the leukemia group of SAKK and the GRAALL group for ALL. He is member of numerous society (ASH, EHA, EBMT, SSH, SSIM, SAKK, SBST, SFGM-TC, GRAALL) and was president of the leukemia group of the SAKK from 2007 to 2013 and member of the SAKK board during the same period. Since July 2012 he has been appointed head of the hemato-oncology & bone marrow transplantation unit and full professor in the Hematology Division of the University Hospital of Geneva (HUG) and since January 2017 Head of the Hematology Division at HUG. He is the actual chair of the CML subcommittee of the CMWP of the EBMT and vice chair of the GRAALL group.
I am currently an Assistant Professor in the Department of Cellular Biotechnologies and Hematology at the Sapienza University of Rome, Italy. After obtaining medical degree and residency in haematology in the Pediatric and Day Units at Sapienza University, I carried out a PhD at Sapienza University and at the Dana–Farber Cancer Institute in Boston, USA, focusing on genome-wide technologies, for the in depth analysis of lymphoid (both chronic, and mainly acute) malignancies.
My main clinical focus is on the management of adult acute lymphoblastic leukaemia, both in terms of translational research as well as development of clinical trials: PI/coordinator of most of the italian clinical trials on acute lymphoblastic leukemia.
PI of 3 academic grants.
Member of the GIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto) and of the EWALL.
Author/co-author of more than 100 peer-reviewed manuscripts.
Jan Cools obtained his PhD degree in 2001 from the KU Leuven with a study on chromosomal defects in leukemia. From 2001 to 2003 he continued his research on the genetic causes of leukemia at Harvard Medical School (Boston, USA). After return to Belgium, he was appointed as assistant professor in 2005 and full professor in 2009 at KU Leuven and since 2008 he is also group leader of VIB, a life sciences institute in Flanders. His research team studies the genetic complexity of acute lymphoblastic leukemia (ALL) and uses that information to develop novel models of leukemia development and novel treatment strategies. For these studies the team is now using single-cell DNA and RNA sequencing to unravel the heterogeneity of ALL at diagnosis and during chemotherapy treatment. He has served as a board member of the European Hematology Association and has been the editor-in-chief of the open access journal Haematologica from 2012 to 2017 and is now editor-in-chief of a new open access hematology journal: HemaSphere (journal of the European Hematology Association).
Hervé Dombret, M.D., is Professor of Hematology at the University of Paris, France. He is Director of the Saint-Louis Institute for Research in Hematology, Immunology and Oncology (member of the Paris Alliance Cancer Research Institutes) and Head of the Clinical Adult Hematology Unit at Hospital Saint–Louis (AP-HP) in Paris. Professor Dombret’s areas of scientific interest include clinical and translational research on acute leukemia ( AML and ALL), as well as preclinical and early clinical R&D in this field. He is President of the Group for Research on Adult ALL (GRAALL) and the Acute Leukemia French Association (ALFA). He is also member of the European LeukemiaNet (ELN) expert panels for AML and ALL, Chair of the European School of Haematology (ESH), Associate Editor for Blood, and reviewer for many journals including the New England Journal of Medicine, Blood, the Journal of Clinical Oncology and TheLancet. Professor Dombret has authored or co-authored more than 350 articles in international peer-reviewed journals, with an h- index of 83.
Dr. Ferrando joined the faculty of the Institute for Cancer Genetics in 2005 where he has developed a highly active research program that combines genomics, biochemical, genetic and experimental therapeutics approaches towards the identification of novel therapies for the treatment of high-risk leukemias and lymphomas. His laboratory has played major roles in the functional analysis of oncogenic NOTCH1 in T-cell acute lymphoblastic leukemia and in deciphering the genetic landscape and mechanisms of transformation, disease progression and relapse in this disease. His work has been recognized with multiple other honors, including the Leukemia and Lymphoma Society Scholar Award, the Pershing Square Sohn Prize for Young Investigators in Cancer Research and the William Dameshek Prize from the American Society of Hematology. He is an elected member the American Society of Clinical Investigation and the Association of American Physicians and currently serves in the editorial board of Leukemia, Blood Cancer Discovery and Genes and Development.
Adele Fielding is Professor of Haematology at UCL, London UK where she is a group leader of a research group working on ALL. She has a clinical practice in acute leukaemia at University College London Hospitals. She trained at UCL Medical School and undertook her PhD at the MRC Centre for Protein Engineering in Cambridge. She held her first faculty position at Mayo Clinic College of Medicine before returning to the UK to take up her current post at UCL. She has been Chief Investigator on the UK’s de novo investigator-initiated trials for adults with ALL, UKALL14 and UKALL60+. Her laboratory was central laboratory for these trials. She has been a past chair of the UK National Cancer Research Institute ALL group. She is presently Chair of the European Working Group on ALL and President of the British Society for Haematology.
Nicola Gökbuget is head of the Study Center of the Department of Hematology/Oncology and the University Cancer Center (UCT) at the University Hospital of the Goethe University Frankfurt, Germany. She is also among the Scientific Task Force Directors at the UCT, the principal investigators of the German Consortium for Translational Cancer Research and the Frankfurt Cancer Institute.
Since more than 20 years she serves as Coordinator of the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL) with more than 140 participating hospitals all over Germany. She Chairs the study group for more than 10 years and has founded and established a national registry ALL with an associated biobank. The GMALL Study Center is a national reference center for adult ALL which provides comprehensive services including advice in challenging situations of clinical management. She is also board member of the German Network for Acute and Chronic Leukemias and the European Leukemia Network (ELN) and founding member of the European Working Group for Adult ALL.
Lia Gore is a Professor with Tenure at the University of Colorado School of Medicine and Chief of Pediatric Hematology/Oncology/Bone Marrow Transplant and Cellular Therapeutics at Children’s Hospital Colorado in the US. Her research is focused on the development of novel cancer therapeutics with an emphasis on high risk diseases and improving access to clinical trials for children. She has been a Principal Investigator or co-Investigator on more than 200 national and international clinical trials, including those that have led to regulatory approval of four drugs for childhood cancer. She is a founding co-director of the University of Colorado’s NCI designated Comprehensive Cancer Center’s Hematological Malignancies Program, and currently serves as a co-director of the Developmental Therapeutics Program. Dr. Gore is the group-wide Vice Chair of the Children’s Oncology Group.
Dieter Hoelzer is Professor of Medicine and Hematology.
His main research is Acute Leukemias. He founded the German Adult ALL Study Group (GMALL) which so far conducted 7 multicenter studies in >145 participating hospitals, where more than 7000 patients were treated.
Prof. Hoelzer was one of the five founders and former President of the European Hematology Association (EHA), currently Vice President of the European and German Competence Network Leukemias. He also founded the European Working Group on Adult Acute Lymphoblastic Leukemia (EWALL).
He was also the President of the Society for Hemato Oncology (SOHO) and a member of the Medical Council and the Foundation Board of the DKMS (Deutsche Knochenmark Spender Datei). He is the chairman of the Medical Advisory Board of the German Carreras Leukemia Foundation.
Prof. Hoelzer received several awards for cancer research and therapy including those of the German Cancer Society, the “Deutsche Krebshilfe”, the Johann-Georg-Zimmermann-Price, the San Salvatore Award and the European Leukemia Network Merit Award. He is an honorary member of the Hematological Societies of Austria, Hungary and Germany (DGHO) and received the doctor honoris causa from the University of Athens and First Pavlov State Medical University of Saint Petersburg.
Prof. Hoelzer is author or co-author of more than 800 peer-reviewed publications and co-author of international textbooks, such as Oxford textbook of Oncology, 20th edition of Harrison´s principles of Internal Medicine (2018) and its forthcoming 21st edition. In addition, he is the first author of the European Guidelines for adult ALL (ESMO) and a recent editorial for the New England Journal of Medicine.
Prof. Dr. med. Dr. h.c. mult. Dieter Hoelzer Director of Internal Medicine University of Frankfurt, Germany firstname.lastname@example.org
Franco-Scottish, Elizabeth Macintyre trained in Internal Medicine and Hematology in the UK, did her PhD in Paris and her Post-Doctoral studies at Harvard. As a Professor in Diagnostic Hematology at Université de Paris (Descartes) she headed Diagnostic Hematology at Necker–Enfants Malades Hospital from 1999-2018 and co-directs the INSERM « Normal and Pathological Lymphoid Differentiation » Team in the Necker Enfants Malades Institute. She is University Vice-President for International Strategy at Université de Paris, President of the European Hematology Association (EHA) from June 2021-23 and a member of the European Scientific foundation of Laboratory Hemato Oncology and of the Biomed Alliance in Europe board.
Mathilde Hunault-Berger, MD PhD, serves as Professor of Clinical Hematology at the University Hospital of Angers, France.
She is also co-head of the translational research program 3i impact “Altérations du système immunitaire inné dans des pathologies dysimmunitaires aigues, chroniques et tumorales : une approche intégrée ».
Professor Hunault’s clinical interests are focused on Acute Lymphoblastic Leukemia and its treatment with special interest in asparaginase management as well as treatment of acute myeloblastic Leukemia.
Stephen P. Hunger, MD received his undergraduate degree in Biology from the Massachusetts Institute of Technology and his medical degree from The University of Connecticut School of Medicine. He completed Pediatrics residency at Johns Hopkins Hospital and Pediatric Hematology Oncology fellowship and post-doctoral research training at Stanford University.
He has held previous faculty positions at the University of Colorado and Children’s Hospital Colorado (Chief of Pediatric Hematology/Oncology/BMT 2007-14)) and the University of Florida (Chief of Pediatric Hematology/Oncology, 2001-07).
Since 2014, Dr. Hunger has been the Chief of the Division of Oncology, the Director of the Center for Childhood Cancer Research and the Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics, Children’s Hospital of Philadelphia, and a Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. He also serves as Associate Director for Pediatric Research of the University of Pennsylvania’s Abramson Cancer Center.
Dr. Hunger specializes in basic, translational and clinical research and treatment regarding children, adolescents and young adults with acute lymphoblastic leukemia (ALL). He has authored more than 325 peer-reviewed manuscripts, almost all on pediatric ALL. He was the Vice-Chairman (2002-2007) and Chairman (2008-2015) of the Children’s Oncology Group (COG) ALL Disease Committee, and has led the COG/NCI High Risk ALL TARGET Project since its inception in 2006. This project has made numerous discoveries on the genomic landscape of childhood ALL that have resulted in precision medicine clinical trials in genetically defined ALL subsets.
Dr. Hunger is the past Chairman of the Scientific Committee of the International Society of Pediatric Oncology (SIOP) and the current Treasurer. He has a major interest in global oncology, with a focus on improving cure rates for children with ALL in low and middle income countries.
Elias Jabbour, MD, is professor of medicine, Department of Leukemia, at The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas. He graduated from the Saint Joseph University School of Medicine, Beirut, and joined the Hotel Dieu de France University Hospital as a resident. He pursued a fellowship in hematology-oncology at the Gustave Roussy Institute, France. In 2003, he joined MDACC as a fellow in the Department of Hematology/Leukemia and Stem Cell Transplantation. He later joined the faculty in the Leukemia Department as assistant professor.
Dr Jabbour is actively involved in research in both acute and chronic forms of leukemia. He was involved in clinical trials that led to the approval of several drugs in chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), and acute lymphoblastic leukemia (ALL). He actively assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. Dr Jabbour has designed more than a dozen clinical trials assessing new combinations for the management of de novo ALL, elderly ALL, and relapsed/refractory disease. Of note, he developed a protocol that has shown significant improvements in survival rates for patients with Philadelphia chromosome-positive ALL. In addition, he developed another innovative treatment approach for these patients by combining blinatumomab, a bispecific monoclonal antibody, with ponatinib, offering a chemotherapy-free regimen that it is hoped will further increase cure rates. Another area on which he focused his research is elderly patients with ALL. The aggressive biology of the disease and elderly patients’ poor tolerance of intensive chemotherapy leads to low survival rates for this patient population.
Dr Jabbour is currently investigating an innovative strategy combining new monoclonal antibodies such as inotuzumab ozogamicin, a conjugated anti-CD22 antibody, and blinatumomab with minimal chemotherapy. If successful, such strategies will likely increase the cure rates of adult patients with ALL to the high level achieved in pediatric patients.
Dr Jabbour has taken an active role in the medical community, participating in numerous scientific meetings. He has authored or co-authored numerous publications (>550 peer-reviewed publications) and abstracts, and serves as a reviewer for many scientific journals. He has received several prestigious awards, among them merit awards from the American Society of Clinical Oncology (2005, 2006, 2007) and the American Society of Hematology (2005, 2006, 2007). He also received several other honors, including the Kimberly Patterson and Shannon Timmons fellowships and the highly coveted Celgene Future Leader in Hematology (2007) and Young Investigator in Hematology (2016) awards.
Dr Henrik Lilljebjörn is a principal research scientist working with translational genomic and functional studies of leukemia. He completed his PhD at the Department of Clinical Genetics, Lund University in 2011. He is now the Head of bioinformatics and his current work is focused on integrative genomic analyses of ALL and AML.
Dr. Litzow is Professor of Medicine in the Division of Hematology at Mayo Clinic. He was the Director of the BMT Program at Mayo from 1992 to 2008 and continues to remain active in the BMT program. He was the Director of the Myeloid Disease Oriented Group in the Division of Hematology from 2002 to 2016. He was appointed chair of the Leukemia Committee of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) in September 2013 after having served as co-chair of the committee since 2001.
Dr. Litzow completed two terms as Vice-Chair for North America for the Center for International Blood and Marrow Transplant Registry (CIBMTR) and was recently appointed as a co-chair of the Acute Leukemia Working Committee of the CIBMTR. He is a member of the Board of Directors of the Foundation for the Accreditation of Cellular Therapy (FACT) and chairs the FACT Technology Committee. He just completed an 8 year term as chair of the Committee on Education for the American Society of Blood and Marrow Transplantation. His research interests include clinical trials for acute and chronic leukemia including blood and marrow transplantation and supportive care of blood and marrow transplant patients. He became board certified in Hospice and Palliative Medicine in 2013 and is a member of the Palliative Medicine Program at Mayo Clinic in Rochester. He has been awarded RO1 funding in the past for the use of autologous dendritic cell therapy for chronic myeloid leukemia. He is the author of nearly 500 manuscripts and multiple book chapters.
Professor David I Marks MB BS PhD FRACP FRCPath is Professor of Haematology and Stem Cell Transplantation. He received his medical education at the University of Melbourne and his clinical training largely at the Royal Melbourne Hospital. He then moved to London for further training in stem cell transplantation with Professor Goldman at the Hammersmith Hospital followed by a 3-year stint in Philadelphia as Assistant Professor in Haematology/Oncology. He returned to the UK in 1996 and was appointed to a consultant position in the Bristol Bone Marrow Transplantation (BMT) Unit (which he directs) and Honorary Chair at the University of Bristol.
Professor Marks’ research focuses on clinical aspects of stem cell transplantation (particularly the use of alternative donors), ALL and infection. In 1999 he worked to initiate the first national transplant trial group and chaired it for 5 years. He was Lead Clinician of the Bristol BMT Unit from 2003–9 and 2014 until 2017. He has a major interest is inotuzumab ozagamicin, authoring 3 publications, and he recently co-authored a review on T-cell ALL in adults in Blood.
He is Transplant Coordinator and Deputy Chair of The National Cancer Research Institute (NCRI) ALL working group, was previously President of the British Society of Blood and Marrow Transplantation (BSBMT) and currently chairs the Adjudication Committee of BSBMT. He is a Member of the American Society for Blood and Marrow Transplantation Practice Guidelines Committee and Vice Chair (Europe) of the Advisory Committee of the Center for International Blood and Marrow Transplant Research. More recently he was appointed Medical Director of IMPACT UK, the new national transplant trials group.
Dr. Shannon Maude is an oncologist in the Cancer Immunotherapy Program at the Children’s Hospital of Philadelphia and an Assistant Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine. After earning her undergraduate degree in Biology from the University of Virginia, Dr. Maude received her M.D. and Ph.D. from the University of Pennsylvania School of Medicine, and completed her residency in pediatrics as well as a fellowship in pediatric hematology-oncology at the Children’s Hospital of Philadelphia. Dr. Maude served as Fellowship Director of the Cancer Immunotherapy and BMT Fellowship at Children’s Hospital of Philadelphia and currently serves as a Medical Director in the Center for Cellular Immunotherapies at the University of Pennsylvania and leads clinical trials of engineered T cell therapies for childhood cancers. Dr. Maude has a special interest in novel therapies for acute lymphoblastic leukemia, particularly targeted therapy approaches and engineered T cell therapy.
Ester Mejstrikova MD, PhD studied general medicine in Prague and received PhD degree in 2008 in Immunology (name of the thesis: Immunological diagnostics and monitoring hematological malignancies in childhood). She discovered key aspects of switching into monocytic lineage in B cell precursor leukemia. She is interested in the mechanisms of the lineage plasticity of normal and leukemic cells, with a focus on minimal residual disease monitoring and diagnostics of hematological and immunological disorders. Recently she works as research associate at Department of Pediatric Hematology and Oncology.
Charles Mullighan is a member of the Department of Pathology, Co-leader of the Hematologic Malignancies Program, Deputy Director of the Comprehensive Cancer Center and Director of the Biorepository at St Jude Children’s Research Hospital. He gained his medical degree from the University of Adelaide, Australia, undertook doctoral studies in immunogenetics in Oxford, and specialist training in hematology and hematopathology at the Institute of Medical and Veterinary Science in Adelaide. He joined St Jude as a postdoctoral fellow in 2004, and joined faculty in 2008.
Professor Mullighan’s research examines the genetic determinants of leukemogenesis and treatment response in acute lymphoblastic leukaemia (ALL) and high risk leukemias. His work has defined the genetic pathogenesis of multiple new subtypes of ALL, and several genetic alterations that have entered the clinic as new diagnostic and therapeutic targets. He is the recipient of numerous awards including an National Cancer Institute Outstanding Investigator Award, the Meyenburg Prize for Cancer Research and the American Society of Hematology Dameshek Prize.
Oliver Ottmann is Professor and Head of Haematology at Cardiff University School of Medicine, UK. Before taking up his current position in 2015, he was Head of the Division of Molecular Therapeutics at the Goethe University in Frankfurt, Germany and Endowed Professor for Molecular Therapy Research of the Deutsche Jose Carreras Leukemia Foundation. He is the Co-Lead of the Cardiff Experimental Cancer Medicine Centre (ECMC), and a member of UK NCRI Clinical Trial Subgroups for AML, ALL and CML.
Professor Ottmann’s scientific interests focus on malignant hematology with a particular emphasis on clinical trials, translational research including biomarker identification and validation, minimal residual disease, pre-clinical drug development as well as mechanisms of leukaemogenesis and drug resistance. He is internationally recognized for his expertise in the therapy for BCR-ABL positive leukemias and as an early phase clinical trialist. Prof. Ottmann is a member of numerous international professional societies including the European Hematology Association (EHA), the European Working Group for Adult ALL (EWALL) and the American Society for Hematology (ASH). Professor Ottmann has authored or co-authored more than 280 articles in international peer-reviewed journals.
Dr. Elizabeth Raetz is a KiDS of NYU Foundation Professor of Pediatrics at the New York University Grossman School of Medicine and she serves as the Director of the Division of Pediatric Hematology/Oncology and Medical Director of the Stephen D. Hassenfeld Children’s Center for Cancer and Blood Disorders. Dr. Raetz has been an active member of the Children’s Oncology Group (COG) ALL Committee for the past 15 years, serving as a study chair for clinical trials in relapsed ALL and disease classification. She presently serves as a Vice Chair for the COG ALL Disease Committee, overseeing frontline clinical trials.
Claire is a Consultant Haematologist and Honorary Senior Lecturer in Haematology at UCL with a particular interest in CAR T-cells for cancer. She completed a PhD in Cellular Immunotherapy at UCL in the laboratory of Professor Karl Peggs and subsequently undertook a Clinician Scientist post in Dr Martin Pule’s Laboratory to work on the UCL CAR T-cell program. Claire’s current role involves pre-clinical development of novel CAR projects, GMP CAR T-cell manufacture and Clinical Trial design for academic CAR T-cell studies at UCL. She is also responsible for the development of a clinical service at UCLH to support patients recruited to CAR T-cell studies and those receiving CAR T on the NHS.
Sarah K Tasian, MD is a pediatric oncologist and physician-scientist at the Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine who is interested in development of molecularly-targeted therapeutics for children with high-risk leukemias. She is a graduate of the University of Notre Dame (BS, BA) and Baylor College of Medicine (MD), and she trained in Pediatrics at Seattle Children’s Hospital and in Pediatric Hematology-Oncology at University of California, San Francisco (UCSF). She specialises in the clinical care of children with hematologic malignancies and is an internationally-recognized expert in pediatric ALL and AML. Her bench-to-bedside and bedside-back-to-bench translational laboratory research program focuses upon testing of kinase inhibitors and chimeric antigen receptor (CAR) T cell immunotherapies in genetic subsets of childhood ALL and AML. Dr Tasian has leadership roles in the Children’s Oncology Group (COG) ALL and Myeloid Diseases committees and Leukemia Lymphoma Society PedAL/EuPAL consortium, is the COG Developmental Therapeutics committee Vice-Chair of Biology for Hematologic Malignancies, and leads or co-leads several national or international early phase clinical trials testing precision medicine therapies in children with high-risk leukemias.
Jan ZUNA is one of the founders of the CLIP (Childhood Leukaemia Investigation Prague) group from Prague, Department of Paediatric Haematology and Oncology at the 2nd Faculty of Medicine of Charles University. He obtained his MD and PhD diplomas and the professorial degree at the 2nd Faculty of Medicine. In between, besides the work in CLIP, he worked as a postdoc in the Leukaemia Research Fund Centre at the Institute of Cancer Research in London. His research interests include molecular genetics and diagnostics of childhood acute lymphoblastic leukaemias, minimal residual disease monitoring, leukaemia origin, or biology of BCR-ABL1-positive leukaemias. He is also devoted fan of Slavia Prague and Crystal Palace football clubs.
Register to the 2nd Translational Research Conference: ACUTE LYMPHOBLASTIC LEUKAEMIA
This site place cookies on your machine for reasons including keeping track of your preferences, collecting aggregated statistics to analyze how our site is used, and to show you ads tailored to your interests. I have read and agree to the ESH GENERAL TERMS AND CONDITIONS OF USE for the ESH “2nd Translational Research Conference: ACUTE LYMPHOBLASTIC LEUKAEMIA” virtual conference. ACCEPT
Privacy, Cookies Policy, General Terms and Conditions of Use
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.